中国发现乙肝病毒复制"开关" 临床治疗或突破
2009年09月14日 10:15 来源:解放日报
同样感染了乙肝病毒,为何有人不久便自愈,有人却会诱发乙肝甚至发展成肝硬化?这个困扰医学界多年的问号,已被部分成功解答。记者日前获悉:复旦大学免疫生物学研究所的专家,在全球首次揭示了乙肝病毒感染新机制,人体原本存在的TRIM22分子,犹如乙肝病毒的“控制开关”,激活它便能抑制病毒复制、防止乙肝生成。研究成果已发表在国际著名刊物《肝脏病学杂志》,业内专家认为,新发现将助推乙肝药物筛选等一系列临床研究。
目前我国乙肝病毒携带者约有1.3亿人,占总人口的十分之一左右,乙肝病毒感染已成为重大公共卫生问题。令人惊奇的是,乙肝病毒感染者中,有两种截然不同的疾病发展趋势:部分感染者经过短暂感染过程后,会自发性地痊愈;部分患者却持续携带病毒,还有25%的携带者会发展成慢性乙肝、肝硬化甚至肝癌。近年来,全球众多科学家针对乙肝病毒这一“奇怪行为”开展研究,却始终找不到原因所在。
四年多前,由复旦大学免疫生物学研究所熊思东教授领衔的团队,着手寻找乙肝病毒感染的机制。他们首先将目光聚焦在一个著名的分子TRIM5α上。熊思东介绍说,这一分子对抑制艾滋病病毒的复制起到关键作用,乙肝病毒与艾滋病毒虽不属同一类病毒,但两者复制的行为十分相像。凭着直觉,研究团队花了一年多时间,历经无数次试验研究TRIM5α,可结果却颇令人扫兴:这个分子与乙肝病毒复制毫无关系。
专家们并没有因此灰心:TRIM分子的“家族”中还有七十余个“兄弟分子”,这其中会不会有对乙肝病毒产生作用的分子?抱着试试看的态度,研究团队将七十余个分子挨个试验。“功夫不负有心人”,终于锁定了TRIM22分子!对于乙肝病毒感染者来说,一旦体内的TRIM22分子被迅速激发,携带者便可诱发相应免疫应答,抑制病毒复制,清除体内的乙肝病毒。这个分子,一定程度上起到了控制乙肝病毒“开关”的作用。
找到了“开关”,将为乙肝临床治疗与研究带来重大改变。专家解释,新发现的分子可能发展为乙肝病毒感染者临床预后、疾病进程重要监测指标,以此协助医生制订治疗方案。医学界向来认为,抗病毒药物对乙肝病毒最有效;新发现却揭示了激活TRIM22分子可抑制病毒复制,这将推动乙肝治疗领域中免疫调节类药物的筛选。此外,有不少中药证实对抑制乙肝病毒有效,却苦于缺乏理论依据,新发现很可能揭示中医药在乙肝领域的作用机理。
TRIM22分子的“亮相”不过是第一步。接下来,熊思东与他的研究团队将对其在乙肝病毒感染中的具体作用进行详细研究,力求找到更多激活TRIM22分子的秘密,为数以亿计的乙肝病毒感染者带来痊愈希望。(顾泳)
Hepatitis B virus replication in China found that the "switch" or a breakthrough in clinical treatment
At 10:15 on September 14, 2009 Source: Jiefang Daily
Also infected with hepatitis B virus, why do people soon heal, some people may even develop into liver cirrhosis induced by hepatitis B? This troubled the medical profession for many years a question mark, has been partially successful answer. Recently, this reporter was informed that: Fudan University Institute of Immune Biology, an expert in the world for the first time revealed a new mechanism of hepatitis B virus infection, human TRIM22 previously existing elements, like the hepatitis B virus "control switch" to activate it can suppress the virus replication, to prevent hepatitis B is generated. Research results have been published in the internationally renowned journals, "Journal of Hepatology", industry experts believe that new findings will boost hepatitis B drug screening and a series of clinical research.
At present, China about 130 million HBV carriers, accounting for around one-tenth of the total population, hepatitis B virus infection has become a major public health problem. Surprisingly, the hepatitis B virus infection, there are two distinct trends of the disease: part of the infected person after a short infection process, it will recover spontaneously; in some patients continues to carry the virus, as well as 25% of the carriers will develop chronic hepatitis B, cirrhosis and even liver cancer. In recent years, many scientists in the world against the hepatitis B virus, this "strange behavior" to carry out research, but still can not find the reason.
More than four years ago by the Institute of Biology, Fudan University, Professor Xiong Sidong immunization led the team, set out to find the mechanism of hepatitis B virus infection. They first focused its attention on a well-known on the molecular TRIM5α. Si-Dong Xiong said that the molecules inhibit HIV replication play a key role in hepatitis B virus and HIV although not belong to the same type of virus, but both are very similar to copying the behavior. With intuition, the research team spent more than a year, after numerous trials research TRIM5α, can be the result we rather people feel disappointed: the molecular and hepatitis B virus replication irrelevant.
Experts has not discouraged: TRIM elements of the "family" there are still more than 70 "brothers elements" of which will have an effect on the hepatitis B virus molecule? Try holding the attitude, the research team will be more than 70 molecules one by one pilot. "Hard work pays off", and finally locked TRIM22 molecule! For the hepatitis B virus infection, once the body TRIM22 molecule was rapidly stimulated, carriers can be induced by appropriate immune response, inhibit viral replication, removal of the hepatitis B virus in vivo. This molecule, to a certain extent played a controlling hepatitis B virus "switch" role.
Found a "switch", clinical treatment and research of hepatitis B will bring significant changes. Experts explained that the newly discovered molecules may lead to a prognosis of hepatitis B virus infection, disease process, key monitoring indicators, thereby assisting doctors to develop treatment programs. The medical profession has always been that the antiviral drugs most effective against hepatitis B virus; new discovery has revealed the activation TRIM22 molecule can inhibit viral replication, which will promote the field of immune regulation of hepatitis B treatment drugs screening. In addition, there are a lot of traditional Chinese medicine proved effective in inhibiting hepatitis B virus, but suffer from a lack of theoretical basis, is likely to reveal new discoveries in the field of medicine in hepatitis B mechanism.
TRIM22 molecule's "appearance" But the first step. Next, Si-Dong Xiong and his research team will be in the hepatitis B virus infection to its specific role in the detailed study, and strive to find more active molecules TRIM22 secret for hundreds of millions of hepatitis B virus infection, bringing healing hope. (Gu Yong)
|